Glaukos (GKOS) to Release Quarterly Earnings on Wednesday

Key Points

• Glaukos (GKOS) is set to release its Q3 2025 earnings results on October 29, with analysts predicting a loss of ($0.27) per share and revenues of $122.548 million.
• In the previous quarter, Glaukos reported a smaller loss than expected at ($0.24) per share, with revenues increasing 29.7% year-over-year to $124.12 million.
• The stock has recent analyst ratings including a "buy" from Goldman Sachs and a consensus rating of "Moderate Buy" with an average target price of $116.92.

Glaukos (NYSE:GKOS - Get Free Report) is expected to announce its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $122.5480 million for the quarter. Glaukos has set its FY 2025 guidance at EPS.Investors can find conference call details on the company's upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 4:30 PM ET.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative net margin of 21.43% and a negative return on equity of 8.59%. The business had revenue of $124.12 million for the quarter, compared to analyst estimates of $115.49 million. During the same period in the previous year, the company earned ($0.52) earnings per share. The business's revenue for the quarter was up 29.7% on a year-over-year basis. On average, analysts expect Glaukos to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Glaukos Price Performance

NYSE GKOS opened at $75.81 on Wednesday. The firm's fifty day simple moving average is $87.33 and its two-hundred day simple moving average is $92.06. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09. Glaukos has a 12-month low of $73.73 and a 12-month high of $163.71. The firm has a market capitalization of $4.35 billion, a P/E ratio of -45.95 and a beta of 0.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GKOS. Smartleaf Asset Management LLC boosted its position in Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 136 shares during the period. AQR Capital Management LLC raised its holdings in shares of Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier's stock valued at $766,000 after purchasing an additional 198 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Glaukos by 0.8% in the 2nd quarter. California State Teachers Retirement System now owns 50,854 shares of the medical instruments supplier's stock valued at $5,253,000 after purchasing an additional 421 shares in the last quarter. Gamco Investors INC. ET AL raised its holdings in shares of Glaukos by 10.7% in the 2nd quarter. Gamco Investors INC. ET AL now owns 8,001 shares of the medical instruments supplier's stock valued at $826,000 after purchasing an additional 773 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co raised its holdings in shares of Glaukos by 1.7% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 60,834 shares of the medical instruments supplier's stock valued at $6,290,000 after purchasing an additional 1,000 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GKOS shares. The Goldman Sachs Group started coverage on shares of Glaukos in a report on Wednesday, October 1st. They issued a "buy" rating and a $103.00 price target on the stock. UBS Group boosted their price objective on shares of Glaukos from $125.00 to $134.00 and gave the company a "buy" rating in a report on Thursday, July 31st. Zacks Research lowered shares of Glaukos from a "strong-buy" rating to a "hold" rating in a report on Friday, August 15th. Truist Financial dropped their price objective on shares of Glaukos from $126.00 to $120.00 and set a "buy" rating on the stock in a report on Monday, September 22nd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and an average target price of $116.92.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.